Tivozanib
Tivozanib is a pharmaceutical drug with 27 clinical trials. Currently 4 active trials ongoing. Historical success rate of 68.4%.
Success Metrics
Based on 13 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
12
Mid Stage
3
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
56.5%
13 of 23 finished
43.5%
10 ended early
4
trials recruiting
27
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Clinical Trials (27)
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
RP2 and Tivozanib for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
Tivozanib + Enzalutamide in Adv Prostate Cancer
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer
Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC
Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
Tivozanib for Recurrent Glioblastoma
Tivozanib As Maintenance Therapy In GYN
RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 27